11 August 2026
Summary
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, met all primary and secondary endpoints in Phase 3 testing and is now advancing toward United States Phase 3 trials, potentially offering the first mechanistically novel oral acne therapy since isotretinoin, according to New York dermatologist Dr. Dennis Porto.
Background: Acne and the Limits of Current Oral Therapy
Acne vulgaris affects roughly 50 million Americans each year, with more than 5 million seeking medical treatment annually. It is a chronic condition, and most patients require repeated or long-term management rather than a single course of therapy.
Despite this, the systemic toolkit has barely changed in a generation. Dermatologists rely largely on oral tetracycline antibiotics, hormonal therapy such as combined oral contraceptives and spironolactone, and isotretinoin. Each carries meaningful limitations: antibiotic use is increasingly constrained by antimicrobial stewardship concerns and updated guideline recommendations for shorter, narrower courses; hormonal therapy is not appropriate for all patients; and isotretinoin, while highly effective, requires pregnancy prevention protocols, laboratory monitoring, and a level of counseling that some patients decline.
The result is a well-recognized gap for patients with moderate to severe acne who are not candidates for, or do not wish to take, existing systemic options.
New Development: What Is Denifanstat
Denifanstat is a first-in-class, once-daily oral small molecule that inhibits fatty acid synthase, the key enzyme in the de novo lipogenesis pathway responsible for approximately 80% of the lipids that make up sebum.
The proposed mechanism is twofold: direct suppression of facial sebum production through inhibition of de novo lipogenesis in human sebocytes, and reduction of inflammation through decreased cytokine secretion and Th17 differentiation. Rather than targeting bacteria or follicular keratinization, the drug addresses sebum overproduction, one of the primary upstream drivers of acne pathogenesis.
Denifanstat is being developed by Ascletis as ASC40 in China and by Sagimet Biosciences elsewhere.
Clinical Data
A randomized, double-blind, placebo-controlled Phase 3 trial enrolled 480 patients with moderate to severe acne, defined as an Investigator's Global Assessment (IGA) score of 3 or 4, randomized 1:1 to denifanstat 50 mg once daily or placebo for 12 weeks.
At week 12, treatment success — an IGA of clear or almost clear with at least a 2-point improvement — was achieved by 33.2% of treated patients versus 14.6% on placebo. Total lesion count fell 57.4% versus 35.4%, and inflammatory lesion count fell 63.5% versus 43.2%. Statistically significant separation from placebo was observed as early as week 4.
Tolerability was favorable. Treatment-emergent adverse events occurred at comparable rates in both arms (58.6% versus 56.3%), and only dry skin (6.3%) and xerophthalmia (5.9%) exceeded 5% incidence in the treatment group. All drug-related adverse events were mild or moderate, with no related Grade 3 or 4 events, no related serious adverse events, and no related discontinuations.
A subsequent open-label Phase 3 extension followed 240 patients for up to 52 weeks of cumulative exposure. Only dry eye (5.5%) and dry skin (5.2%) reached 5% incidence, all treatment-related events remained mild to moderate, and efficacy measures continued to improve beyond week 12.
Regulatory Status
A New Drug Application for denifanstat in moderate to severe acne was accepted by China's National Medical Products Administration in December 2025. Sagimet has announced plans to file an Investigational New Drug application in the United States and to initiate a US Phase 3 trial in moderate to severe acne in the second half of 2026. A follow-on topical FASN inhibitor is also in early clinical development.
Expert Commentary
"Acne is one of the most common conditions we treat, and yet our oral options have not meaningfully changed in about forty years. We are essentially choosing between antibiotics, which the entire specialty is trying to use less of, hormonal therapy, which is not appropriate for every patient, and isotretinoin, which is remarkably effective but comes with monitoring and pregnancy prevention requirements that some patients simply will not accept. A once-daily oral medication that turns down sebum production at the level of lipid synthesis, without being an antibiotic and without being a retinoid, is exactly what dermatologists have been asking for. What I find most encouraging is that the Phase 3 data showed separation from placebo as early as four weeks, and the tolerability signal so far is mostly dry skin and dry eyes rather than anything alarming. If the US trials confirm what has been seen abroad, this could genuinely change how we approach moderate to severe acne. My colleagues and I are watching this one very closely," said Dr. Dennis Porto, a board-certified Mohs surgeon and dermatologist in New York City.
Clinical Significance and Outlook
If US Phase 3 data replicate the results reported to date, denifanstat would represent the first new oral mechanism of action approved for acne in decades and the first non-antibiotic, non-hormonal, non-retinoid systemic option available to dermatologists.
That would be particularly meaningful for patients who have failed or cannot tolerate topical therapy, for patients seeking to avoid prolonged antibiotic exposure, and for patients who are unwilling or unable to pursue isotretinoin.
Important caveats remain. The pivotal efficacy data to date come from a trial population in China, US trials have not yet begun, and there are no head-to-head comparisons against isotretinoin or oral antibiotics. Long-term safety, durability of response after discontinuation, relapse rates, and optimal patient selection all remain to be established. Dermatologists will be following the US program closely.
Dr. Dennis Porto, MD, MPH, FAAD is a double board-certified dermatologist and Mohs micrographic surgeon. He completed a skin cancer research fellowship and a Master of Public Health at Harvard and holds a faculty appointment at Mount Sinai, where he teaches skin cancer surgery. He offers virtual dermatology consultations through skincare.md.
Media inquiries and interview requests may be directed through the contact information at skincare.md.